Participant flow

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) · Source last updated 2021-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. FGFR Inhibitor AZD4547: Given PO

   id

   FG000

   title

   Treatment (AZD4547)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Ineligible

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Never started treatment

   3. reasons

      1. group Id

         FG000

         num Subjects

         12

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Death

   5. reasons

      1. group Id

         FG000

         num Subjects

         25

      type

      Disease progression

   6. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Other diseases

   7. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Withdrawal by Subject

   8. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Clinical concerns for progression and increasing tumor marker

   9. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Symptomatic decline

   10. reasons

       1. group Id

          FG000

          num Subjects

          1

       type

       Pogression of the lymphadenopathy

   11. reasons

       1. group Id

          FG000

          num Subjects

          1

       type

       Clinical progression

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         52

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         50

      type

      Started Protocol Therapy

   3. achievements

      1. group Id

         FG000

         num Subjects

         49

      type

      Eligible

   4. achievements

      1. group Id

         FG000

         num Subjects

         48

      comment

      2 patients ineligible, 1 patient never started treatment, 1 patient both ineligible and never started treatment. This is the primary analysis population.

      type

      Eligible and Started Protocol Therapy

   5. achievements

      1. group Id

         FG000

         num Subjects

         49

      comment

      1 of the 50 treated patients had no adverse events reported

      type

      Reported Adverse Events Data

   6. achievements

      1. group Id

         FG000

         num Subjects

         0

      comment

      Treatment continued until disease progression or intolerability.

      type

      COMPLETED

   7. achievements

      1. group Id

         FG000

         num Subjects

         52

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For subprotocol W, patients had to have tumors harboring aberrations in FGFR 1-3.

recruitment Details

Subprotocol W was activated on May 31, 2016. 70 patients were assigned to Subprotocol W after screening, all from screening cohort. Of the 70 patients, 52 patients from 47 different sites enrolled in the study between July 2016 and June 2017.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice